Assertio Therapeutics Stock Performance
| ASRT Stock | USD 18.57 2.06 12.48% |
Assertio Therapeutics holds a performance score of 20 on a scale of zero to a hundred. The firm shows a market beta of 0.52, which conveys generally lower market sensitivity than the broad market. With a sub-1 beta, Assertio Therapeutics typically participates in market rallies at a reduced pace while often limiting downside exposure.
Risk-Adjusted Performance
Constructive
Weak | Strong |
Assertio Therapeutics currently ranks below 20% of comparable global equities and portfolios when recent risk-adjusted returns are measured across a 90-day horizon. The main point is that return should be judged together with the volatility required to produce it. In spite of comparatively uncertain basic indicators, Assertio Therapeutics unveiled solid returns over the last few months and may actually be approaching a breakup point. Learn More
Actual Historical Performance (%)
One Day Return 17.93 | Five Day Return 20.07 | Year To Date Return 80.63 | Ten Year Return -97.89 | All Time Return -92.66 |
1 | Is Assertio Stock Outpacing Its Medical Peers This Year | 01/14/2026 |
2 | Wall Street Analysts Think Assertio Could Surge 249.87 percent Read This Before Placing a Bet | 01/16/2026 |
3 | Disposition of 8959 shares by Stark David Matthew of Assertio Therapeutics at 0.7597 subject to Rule 16 b-3 | 02/04/2026 |
4 | Disposition of 825 shares by Paul Schwichtenberg of Assertio Therapeutics at 12.74 subject to Rule 16 b-3 | 02/10/2026 |
5 | Disposition of 2778 shares by Ajay Patel of Assertio Therapeutics subject to Rule 16 b-3 | 02/18/2026 |
6 | Disposition of 1143 shares by Paul Schwichtenberg of Assertio Therapeutics subject to Rule 16 b-3 | 02/20/2026 |
7 | Acquisition by Mark Reisenauer of 26667 shares of Assertio Therapeutics at 11.77 subject to Rule 16 b-3 | 03/02/2026 |
8 | Assertio Holdings, Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on March 16, 2026 | 03/03/2026 |
9 | Assertio Q 4 Earnings Snapshot | 03/16/2026 |
10 | Assertio Q 4 Earnings Call Highlights | 03/17/2026 |
11 | Disposition of 17150 shares by Ajay Patel of Assertio Therapeutics subject to Rule 16 b-3 | 03/20/2026 |
12 | 12 Health Care Stocks Moving In Tuesdays Intraday Session | 03/24/2026 |
| Begin Period Cash Flow | 50.6 M | |
| Total Cashflows From Investing Activities | -12 M |
Assertio | Build portfolio with Assertio Stock |
Relative Risk vs. Return Landscape
If you had invested $ 994.00 in Assertio Therapeutics on December 25, 2025 and sold it today you would have earned a total of $ 863.00 from holding Assertio Therapeutics or generated 86.82% return on investment over 90 days. Assertio Therapeutics is currently generating a 1.1155% daily expected return and carries 4.2904% risk (volatility on return distribution) over a 90-day horizon. In different words, 38% of stocks are less volatile than Assertio, and 78% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Target Price Odds to finish over Current Price
The mean-reverting behavior of Assertio Stock price is a cornerstone of quantitative forecasting models. Studies have found that some stocks are persistently mispriced, with spreads correcting only when dynamics shift. Embedded risk premiums affect the speed at which mispriced stocks converge to their fair values. This concept remains a foundational input for building forecasting models around Assertio Stock price behavior.
| Current Price | Horizon | Target Price | Odds moving above the current price in 90 days |
| 18.57 | 90 days | 18.57 | near 1 |
Probability analysis for this stock suggests that the odds of Assertio Therapeutics moving above the current price in 90 days from now are near 1 . Recent return data has shown a distribution that skews above the current level over this window. (This density function focuses attention on the most probable trading range for Assertio Stock over the next 90 days).
Assertio Therapeutics Price Density |
| Price |
Predictive Modules for Assertio Therapeutics
The challenge of forecasting Assertio Therapeutics mirrors the broader difficulty of predicting stock market movements. While perfect accuracy is unattainable, applying multiple models remains a core part of sound stock analysis. Market surprises are inevitable, but disciplined forecasting still improves overall investment decision-making. Applying diverse stock forecasting tools remains one of the most practical paths to better investment decisions.The mean reversion effect in Assertio Therapeutics is stronger when the initial deviation was driven by sentiment rather than fundamentals. Such deviations have sometimes corrected when the initial catalyst fades, though timing remains uncertain. The degree to which Assertio Therapeutics' exhibits mean reversion depends on how efficiently the market prices new information. Short-term deviations can persist and even widen before correcting, making position sizing critical.
Primary Risk Indicators
Over recent decades, the stock market has seen multiple large corrections and recoveries affecting Assertio Therapeutics. Both sharp declines and powerful rallies have tested investor discipline in Assertio Therapeutics. Tracking Assertio Therapeutics' volatility and fundamental risk indicators provides a framework for managing downside exposure. This framework helps investors in Assertio Therapeutics make more informed hedging and position-sizing decisions.α | Alpha over Dow Jones | 0.71 | |
β | Beta against Dow Jones | 0.52 | |
σ | Overall volatility | 1.32 | |
Ir | Information ratio | 0.18 |
Investor Alerts and Insights
Investors who use alerts for Assertio Therapeutics can respond more quickly to important stock events. Checking Assertio Therapeutics notifications regularly is a straightforward way to stay on top of actionable developments. Combining Assertio Therapeutics alerts with broader market context improves the quality of investment decisions. Consistent monitoring through alerts builds a more complete picture of Assertio Therapeutics over time.| Assertio Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported previous year's revenue of 118.71 M. Net Loss for the year was -30.38 M with profit before overhead, payroll, taxes, and interest of 83.33 M. | |
| Assertio Therapeutics currently holds about 52.26 M in cash with -28.18 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.09. | |
| Assertio Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Latest headline from benzinga.com: 12 Health Care Stocks Moving In Tuesdays Intraday Session |
Price Density Drivers
For investors analyzing Assertio Therapeutics, understanding buyer and seller positioning dynamics is essential for price analysis. Monitoring these dynamics helps anticipate short-term price movements and gauge current market conditions. Assessing Assertio Therapeutics' price density drivers provides insight into whether recent moves are fundamental or tactical. These indicators, paired with fundamental analysis, offer a more complete view of Assertio Therapeutics.
| Common Stock Shares Outstanding | 6.4 M | |
| Cash And Short Term Investments | 63.4 M |
Assertio Therapeutics Fundamentals Growth
The market value of Assertio Stock depends on how investors perceive Assertio Therapeutics' financial strength. Earnings growth, revenue momentum, profitability ratios, and debt levels drive Assertio Stock valuation. The financial health of Assertio Therapeutics is the primary driver of Assertio Stock market performance over time. Investors pricing Assertio Stock focus on Assertio Therapeutics' core financial fundamentals and growth trajectory.
| Return On Equity | -0.28 | |||
| Return On Asset | -0.039 | |||
| Profit Margin | -0.26 % | |||
| Operating Margin | -1.05 % | |||
| Current Valuation | 62.71 M | |||
| Shares Outstanding | 6.45 M | |||
| Price To Earning | 4.93 X | |||
| Price To Book | 0.92 X | |||
| Price To Sales | 0.90 X | |||
| Revenue | 118.71 M | |||
| Gross Profit | 83.33 M | |||
| EBITDA | 12.78 M | |||
| Net Income | -30.38 M | |||
| Cash And Equivalents | 52.26 M | |||
| Cash Per Share | 1.09 X | |||
| Total Debt | 39.12 M | |||
| Debt To Equity | 0.49 % | |||
| Current Ratio | 1.00 X | |||
| Book Value Per Share | 14.63 X | |||
| Cash Flow From Operations | -28.18 M | |||
| Earnings Per Share | -0.32 X | |||
| Market Capitalization | 106.41 M | |||
| Total Asset | 266.97 M | |||
| Retained Earnings | -703.5 M | |||
| Working Capital | 89.13 M | |||
| Current Asset | 5.15 M | |||
| Current Liabilities | 492.4 K | |||
Performance Metrics & Calculation Methodology
Return quality for Assertio Therapeutics evaluates how consistent and repeatable performance has been across periods. Inconsistent returns may indicate sensitivity to regime shifts or concentrated factor exposure. Assertio Therapeutics shows ROE of -28.25%, ROA of -3.9%.
For Assertio Therapeutics, this section uses periodic company reporting and market reference feeds and standardizes the results for cross-period comparison. Where analyst coverage exists, consensus estimates are factored in. Intraday timing differences may exist. Return and risk statistics are calculated from historical price series.